Dr. Lee Andrew Davis Jr., MD Internal Medicine - Interventional Cardiology Medicare: Accepting Medicare Assignments Practice Location: 7500 Dollarway Rd, Suite 301, White Hall, AR 71602 Phone: 870-850-0800 Fax: 870-850-0801 |
Ali Al-nashif, M.D. Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 7240 Sheridan Rd Ste 101, White Hall, AR 71602 Phone: 870-247-6105 Fax: 870-247-6106 |
Dr. Maher Alesali, MD Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 7500 Dollarway Rd, Suite 404, White Hall, AR 71602 Phone: 870-879-9595 Fax: 870-879-9599 |
News Archive
Merck today announced that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, will be presented in oral plenary sessions at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is taking place from Oct. 29 through Nov. 2 in Boston. Results for boceprevir in response-guided therapy strategies, which evaluated treatment durations shorter than current standard therapy, will be presented during the meeting.
In the study, the researchers have examined how molecules added to the skin through various liquids and creams affect the skin, and how the same molecules are affected by being inside the skin.
The treatment of cryptococcal meningitis in resource-limited settings is most effective with a short 1-week course of amphotericin induction therapy coupled with high-dose fluconazole for at least 2 weeks, a Ugandan study suggests.
Nventa Biopharmaceuticals Corporation announced that the European Patent Office has granted Patent Number EP 941,315 to Nventa.
› Verified 6 days ago